Home FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Mercks KEYTRUDA (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma
 

Keywords :   


FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Mercks KEYTRUDA (pembrolizumab) in Relapsed or Refractory Classical Hodgkin Lymphoma

2016-12-01 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or for patients who have relapsed after three or more prior lines of therapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: review application license classical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
14.11
14.115
14.11MTGfoil
14.11
14.11sw14000XH 8000
14.11katie
14.11EX 330 HP SAR
14.11 M1
More »